TY - JOUR T1 - Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site of Antagonist Action JF - Molecular Pharmacology JO - Mol Pharmacol SP - 548 LP - 558 DO - 10.1124/molpharm.120.000124 VL - 98 IS - 5 AU - Kathryn L. Reichard AU - Keionna A. Newton AU - Zeena M.G. Rivera AU - Paulo M. Sotero de Menezes AU - Selena S. Schattauer AU - Benjamin B. Land AU - Charles Chavkin Y1 - 2020/11/01 UR - http://molpharm.aspetjournals.org/content/98/5/548.abstract N2 - The prototypical member of the receptor-inactivating kappa opioid receptor (KOR) antagonists, norbinaltorphimine (norBNI), produces prolonged receptor inactivation by a cJun kinase mechanism. These antagonists have potential therapeutic utility in the treatment of stress disorders; however, additional preclinical characterization is necessary to understand important aspects of their action. In this study, we report that norBNI does not work as effectively in female mice as in males because of estrogen regulation of G protein receptor kinase (GRK); pretreatment of ovary-intact female mice with the selective GRK2/3 inhibitor, Compound 101, made females equally sensitive to norBNI as males. Prior observations suggested that in vivo treatment with norBNI does not produce long-lasting inhibition of KOR regulation of dopamine release in the nucleus accumbens. We assessed the persistence of norBNI receptor inactivation in subcellular compartments. Fast-scan cyclic voltammetry recordings confirmed that presynaptic inhibition of dopamine release by the KOR agonist U69,593 was not blocked by in vivo pretreatment with norBNI under conditions that prevented KOR-mediated aversion and analgesia. We employed a novel in vivo proxy sensor of KOR activation, adenovirus associated double floxed inverted–HyPerRed, and demonstrated that KOR activation stimulates cJun kinase–dependent reactive oxygen species (ROS) production in somatic regions of ventral tegmental area dopamine neurons, but did not activate ROS production in dopamine terminals. The compartment selective action helps explain how dopamine somatic, but not terminally expressed, KORs are inactivated by norBNI. These results further elucidate molecular signaling mechanisms mediating receptor-inactivating KOR antagonist action and advance medication development for this novel class of stress-resilience medications.SIGNIFICANCE STATEMENT Kappa opioid receptor (KOR) antagonists are being developed as novel proresilience therapeutics for the treatment of mood and substance use disorders. This study showed that the long-acting KOR antagonists are affected by both the sex of the animal and the subcellular compartment in which the receptor is expressed. ER -